非小细胞肺癌ctDNA监测耐药相关伴随基因研究进展

Research progress on dynamic monitoring of ctDNA and drug resistance related concomitant mutations in non⁃small cell lung cancer

肺癌靶向治疗显著延长了患者的生存时间,已成为晚期驱动基因阳性非小细胞肺癌患者标准治疗。但肺癌患者的基因状态是动态变化的,通过动态监测基因状态的变化,可早期发现与肺癌疾病进展相关差异基因和伴随基因,从而更加精准地实现对肺癌靶向治疗全程管理的全方位掌握。根据精确基因检测指导下的靶向药应用,有助于为患者提供更切实有效、更长期稳定的个体化靶向治疗指导,达到最佳临床获益。

Owing to significantly prolonged survival,targeted therapy has become standardized recommendation for advanced non‐small cell lung cancer patients with mutated driver genes.However,the genetic status of lung cancer patients is dynam‐ic.By dynamically monitoring the evolution of genes status,differential genes and concomitant genes related to progressive disease could be confirmed early,so as to achieve a more accurate and comprehensive insight of the whole process management of targeted therapy for lung cancer patients.Under the guidance of accurate genetic testing results,it is helpful to provide patients with more effective,long‐term,and stable individualized targeted therapy.